Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | IL1RN | P18510 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579423 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL3586118 | 0.79 | ALDH1A1 (0.46) | MAPTLMNAKMT2AMEN1 | |
| SCHEMBL3579591 | 0.72 | MEN1 (0.43) | SMN1; SMN2MAPTLMNAPOLBGAA | |
| SCHEMBL3589987 | 0.72 | CRHBP (0.41) | MAPTLMNAGAAKMT2AMEN1 | |
| SCHEMBL3578837 | 0.71 | CRHBP (0.54) | SMN1; SMN2MAPTLMNAGAA | |
| SCHEMBL3583102 | 0.69 | SLC1A3 (0.34) | SMN1; SMN2MAPTLMNAPOLBGAA | |
| SCHEMBL3870878 | 0.67 | GAA (0.53) | MAPTPOLBGAAKMT2AMEN1 | |
| SCHEMBL3583557 | 0.67 | ACLY (0.35) | KMT2AMEN1 | |
| SCHEMBL3576836 | 0.67 | CYP1A2 (0.53) | SMN1; SMN2MAPTLMNAKMT2AMEN1 | |
| SCHEMBL3606479 | 0.66 | MAPK1 (0.43) | SMN1; SMN2TDP1MAPTLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-05-06 | — | — | US | disclosed |
| EP-2076492-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Merck & Co., Inc. (US) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008054605-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113421-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RTF1, RNGTT, POLR2E | SMN1; SMN2 2261/4885TDP1 106/4885MAPT 1265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.